Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
In cystic fibrosis patients with Pseudomonas aeruginosa colonization and increasing pulmonary infection, ceftazidime 150 mg/kg/day was compared with 320 mg/kg/day. Changes in clinical findings, laboratory tests, pulmonary function and chest radiographs were evaluated after 14 days of treatment in hospital. Both treatments were associated with a significant improvement, but the higher dose did not offer an additional benefit. An increase in alanine aminotransferase (ALT) occurred after both treatments; with a significantly greater increase after the high-dose therapy (mean increase +/- S.E.M. 8% +/- 2% vs 2% +/- 1 %; P < 0.01). All but one of the ALT values after treatment were within normal limits.
De Boeck
K
K
Department of Pediatrics, University Hospital of Leuven, Belgium. christiane.deboeck@uz.kuleuven.ac.be
Breysem
L
L
D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D001799:Blood Sedimentation / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003404:Creatinine / Q000097:blood; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D008176:Lung Volume Measurements; D008297:Male; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D010359:Patient Readmission; D010976:Platelet Count / Q000187:drug effects; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D012008:Recurrence; D012129:Respiratory Function Tests; D013997:Time Factors; D016896:Treatment Outcome; D014680:Veins; D014797:Vital Capacity / Q000187:drug effects / Q000502:physiology
D002511:Cephalosporins; D006454:Hemoglobins; D002442:Ceftazidime; D003404:Creatinine; D000410:Alanine Transaminase